Literature DB >> 24022854

Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria.

Brent Wood1, Dragan Jevremovic, Marie C Béné, Ming Yan, Patrick Jacobs, Virginia Litwin.   

Abstract

Multi-color flow cytometry is a unique technology, which enables the analysis of heterogeneous cellular systems and provides multiparametric information on a cell-by-cell basis. A variety of factors contribute to the complexity of validating cell-based flow cytometric methods, including the lack of fully characterized cellular reference materials and the difficulty in obtaining, or creating, samples with varying levels of a given cell type or varying levels of expression of a given antigen. This document summarizes validation requirements and describes validation strategies for quasi-quantitative and qualitative cell-based flow cytometric assays.
© 2013 International Clinical Cytometry Society.

Keywords:  Cytometry; accuracy; imprecision; sensitivity; specificity

Mesh:

Substances:

Year:  2013        PMID: 24022854     DOI: 10.1002/cyto.b.21108

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  28 in total

Review 1.  Flow Cytometry, a Versatile Tool for Diagnosis and Monitoring of Primary Immunodeficiencies.

Authors:  Roshini S Abraham; Geraldine Aubert
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies.

Authors:  Sindhu Cherian; Maryalice Stetler-Stevenson
Journal:  Curr Protoc Cytom       Date:  2018-09-13

3.  Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Authors:  Maryalice Stetler-Stevenson; Bruno Paiva; Lloyd Stoolman; Pei Lin; Jeffrey L Jorgensen; Alberto Orfao; Jacques Van Dongen; Andy C Rawstron
Journal:  Cytometry B Clin Cytom       Date:  2015-07-06       Impact factor: 3.058

4.  Data quality in drug discovery: the role of analytical performance in ligand binding assays.

Authors:  Hermann Wätzig; Imke Oltmann-Norden; Franziska Steinicke; Hassan A Alhazmi; Markus Nachbar; Deia Abd El-Hady; Hassan M Albishri; Knut Baumann; Thomas Exner; Frank M Böckler; Sami El Deeb
Journal:  J Comput Aided Mol Des       Date:  2015-06-13       Impact factor: 3.686

Review 5.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

6.  Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Paul K Wallace
Journal:  Curr Protoc Cytom       Date:  2019-07-17

Review 7.  Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.

Authors:  Franklin Fuda; Weina Chen
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

8.  A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.

Authors:  Michael Keeney; Brent L Wood; Benjamin D Hedley; Joseph A DiGiuseppe; Maryalice Stetler-Stevenson; Elisabeth Paietta; Gerard Lozanski; Adam C Seegmiller; Bruce W Greig; Aaron C Shaver; Lata Mukundan; Howard R Higley; Caroline C Sigman; Gary Kelloff; J Milburn Jessup; Michael J Borowitz
Journal:  Cytometry B Clin Cytom       Date:  2017-05-05       Impact factor: 3.058

Review 9.  Methods of Detection of Measurable Residual Disease in AML.

Authors:  Yi Zhou; Brent L Wood
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

10.  Report of the results of the International Clinical Cytometry Society and American Society for Clinical Pathology workload survey of clinical flow cytometry laboratories.

Authors:  Kristy Wolniak; Charles Goolsby; Sarah Choi; Asma Ali; Nina Serdy; Maryalice Stetler-Stevenson
Journal:  Cytometry B Clin Cytom       Date:  2016-08-03       Impact factor: 3.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.